Premium
Inhibition of human gastric secretion by ICI 162,846‐a new histamine H2‐receptor antagonist.
Author(s) -
Wilson JA,
Johnston DA,
Penston J.,
Wormsley KG
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb05234.x
Subject(s) - pepsin , histamine , gastric acid , medicine , antagonist , secretion , histamine h2 receptor , endocrinology , stomach , pharmacology , placebo , receptor antagonist , chemistry , receptor , enzyme , biochemistry , alternative medicine , pathology
The inhibitory effect of ICI 162,846, a new histamine H2‐receptor antagonist, on gastric secretion of acid and pepsin was studied in 10 healthy male volunteers, aged 21‐30 years. Single doses of 0.5, 1.0, 2.5 and 5.0 mg were given orally at 18:00 h. Overnight 12 h gastric secretion of acid was reduced by 69, 81, 91 and 95%, respectively. The inhibition of nocturnal output of pepsin was less than acid, with median decreases of 21, 42, 73 and 87%, respectively, of the output after administration of placebo. Intragastric concentration of acid, and values of intragastric pH, during the following 12 h of the day were not significantly affected by any of the doses of the drug. We conclude that ICI 162,846 is a powerful inhibitor of gastric secretion, with potential for use in the treatment of peptic diseases.